32222-06-3
32222-06-3 structure
- Name: Calcitriol
- Chemical Name: calcitriol
- CAS Number: 32222-06-3
- Molecular Formula: C27H44O3
- Molecular Weight: 416.637
- Catalog: API Vitamins and minerals Vitamin AD drugs
- Create Date: 2018-09-03 16:15:34
- Modify Date: 2026-06-29 19:40:51
-
Calcitriol is the most active metabolite of vitamin D and also a vitamin D receptor (VDR) agonist.
| Name | calcitriol |
|---|---|
| Synonyms |
(1α,3β,5Z,7E)-9,10-Secocholesta-5,7,10-triene-1,3,25-triol monohydrate
dihydroxyvitamind3 ro215535 Calcitriol (Rocaltrol) 1A25-dihydroxycholecalciferol(+4℃) 9,10-SECOCHOLESTA-5Z,7E,10-TRIENE-1ALPHA,3BETA,25-TRIOL Calcijex Calcitriol (10 mg) (COLD SHIPMENT REQUIRED) 1α,25-Dihydroxyvitamin D3 VITAMIN D3, 1ALPHA,25-DIHYDROXY 1α,25-Dihydroxyvitamin D3 monohydrate Solbone P 9,10-Secocholesta-5,7,10-triene-1,3,25-triol, (1.alpha.,3.beta.,5Z,7E) CALCITRIOL rocaltrol (1R,3S,5Z)-5-[(2E)-2-[(1R,3aS,7aR)-1-[(2R)-6-hydroxy-6-methylheptan-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol (5z,7e)-9,10-secocholesta-5,7,10-triene-1-alpha,3-beta,25-triol Panbonis 1,25- DIHYDROXYVITAMIN D3 (6,19,19-D3) Solution 1-alpha,25-dihydroxy-cholecalcifero 1ALPHA,25-DIHYDROXYVITAMIN D3 1α,25-Dihydroxycholecalciferol monohydrate 7,10-triene-1,3,25-triol,(1alpha,3beta,5z,7e)-10-secocholesta-5 (5z,7e)-(1s,3r)-9,10-secocholesta-5,7,10-triene-1,3,25-triol 1,25-dihydroxycholecalciferol (1R,3S,5Z)-4-Methylene-5-[(2E)-2-[(1R,3aS,7aS)-octahydro-1-[(1R)-5-hydroxy-1,5-diMethylhexyl]-7a-Methyl-4H-inden-4-ylidene]ethylidene]-1,3-cyclohexanediol (1a,3b,5Z,7E)- 9,10-Secocholesta-5,7,10-triene-1,3,25-triol 1ALPHA,25-DIHYDROXYCHOLECALCIFEROL 7,10-triene-1,3,25-triol,(1-alpha,3-beta,5z,7e)-10-secocholesta-5 1A, 25-DIHYDROXYCHOLECALCIFEROL (1S,3R)-9,10-Secocholesta-5,7,10-triene-1,3,25-triol Silkis EINECS 250-963-8 (5z,7e)-9,10-secochesta-5,7,10-triene-1-alpha,3-beta,25-triol 1a,25-dihydroxy-cholecalcifero MFCD00867079 1,25-Dihydroxyvitamin-D3-[2H3] 1ALPHA,25-DIHYDROXY-VITAMIN D8 Rocalirol 1a,25-Dihydroxyvitamin Toptriol Calcitriol (10 mg)F0E0620.993mg/mg(ai) (1ALPHA,3BETA,5Z,7E)-9,10-SECOCHOLESTA-5,7,10-TRIENE-1,3,25-TRIOL Soltriol aslpha,25-Dihydroxycholecalciferol Topitriol Vitamin D3, 1a,25-Dihydroxy 1α,25-Dihydroxycalciferol solution 1,25-DIHYROXYCHOLECALIFEROL 9,10seco(5z,7e)-5,7,10-cholestatriene-1alpha,3beta,25-triol 1,25-dhcc 1,25- DIHYDROXYVITAMIN D3 (6,19,19-D3) Calcitriol-D3 Calcitrio 1α,25-Dihydroxyvitamin D3 solution 1,25-dihydroxyvitamind 9,10-Secocholesta-5,7,10-triene-1,3,25-triol, (1α,3β,5Z,7E) 1,25-DihydroxyvitaMin D3 Calcitriol 1,25-(OH)2-D3 (1R,3S,Z)-5-((E)-2-((1R,3aS,7-1-((R)-6-hydroxy-6-methylhtan-2-yl)-7a-methyl-octahydroinden-4-ylidene)ethylidene)-4-methylenecyclohexane-1,3-diol 1α,25-Dihydroxyvitamin D3,1α,25-Dihydroxycholecalciferol, Calcitriol (1R,3S,5Z)-5-{2-[(1R,3aS,4E,7-1-[(2R)-6-hydroxy-6-Methylhtan-2-yl]-7a-Methyl-octahydro-1H-inden-4-ylidene]ethylidene}-4-Methylidenecyclohexane-1,3-diol |
| Description | Calcitriol is the most active metabolite of vitamin D and also a vitamin D receptor (VDR) agonist. |
|---|---|
| Related Catalog | |
| Target |
Human Endogenous Metabolite |
| In Vitro | Calcitriol exerts antiproliferative effects on cervical cancer cells in vitro. Cells decrease by 12.8% when treated with 100 nM Calcitriol for 6 days, compare with control. Inhibition of cell proliferation becomes more pronounced with the increase in Calcitriol concentration. The decrease is 26.1% and 31.6% for 200 and 500 nM Calcitriol, respectively. Treatment with Calcitriol for 72 h induces an evident accumulation of cells in the G1 phase, with approximately 66.18% in 200 nM and 78.10% in 500 nM, compare with the control (24.36%). Calcitriol treatment significantly decreases HCCR-1 protein expression compare with the control in a time- and dose-dependent manner[1]. Calcitriol significantly increases ERα mRNA in a dose dependent manner with an EC50 of 9.8×10-9 M[2]. |
| In Vivo | Chronic treatment with Calcitriol (150 ng/kg per day for 4.5 months) improves the relaxations (pD2: 6.30±0.09, Emax: 68.6±3.9% in Calcitriol-treated OVX, n=8). Renal blood flow in OVX rats is reduced in both kidneys, and the flow is restored by Calcitriol treatment. The increased expression of COX-2 and Thromboxane-prostanoid (TP) receptor in OVX rat renal arteries is reduced by chronic calcitriol administration[3]. High- and low-dose Calcitriol treatment significantly decreases the systolic blood pressure (SBP) in the fructose-fed rats by 14±4 and 9±4 mmHg, respectively, at Day 56. High-dose Calcitriol treatment (20 ng/kg per day) significantly increases serum ionized calcium level (1.44±0.05 mmol/L) compare with the other groups[4]. |
| Cell Assay | HeLa S3 cells are plated at a density of 1,000 cells/well in 96-well plates of Dulbecco’s modified Eagle’s medium (DMEM) with 10% fetal bovine serum (FBS), treated with 1% ethanol (control) or various concentrations of Calcitriol (100, 200, and 500 nM) for 72 h. A Cell Counting Kit8 (CCK-8) is used to determine cell proliferation. At 24, 48, 72, 96, 120, and 144 h after culturing with 200 nM Calcitriol, cells are harvested for analysis. Three independent experiments are performed in quadruplicate[1]. |
| Animal Admin | Adult female Sprague-Dawley rats weighing 200 to 220g are used in this study. Rats are housed in a temperature-controlled room (~23°C) with a 12-h light/dark cycle. The animals have free access to a standard diet and water. Ovariectomy (OVX) is performed on rats. At 6 months after the surgical procedure, the OVX rats are randomly assigned to either treatment with vehicle dimethyl sulfoxide (OVX+vehicle) or Calcitriol (150 ng/kg daily, OVX+calcitriol). Calcitriol treatment is given by oral gavage and lasted or 4.5 months. Blood pressure and serum Calcitriol level are measured[3]. |
| References |
| Density | 1.1±0.1 g/cm3 |
|---|---|
| Boiling Point | 565.0±50.0 °C at 760 mmHg |
| Melting Point | 119-1210C |
| Molecular Formula | C27H44O3 |
| Molecular Weight | 416.637 |
| Flash Point | 238.4±24.7 °C |
| Exact Mass | 416.329041 |
| PSA | 60.69000 |
| LogP | 6.12 |
| Vapour Pressure | 0.0±3.5 mmHg at 25°C |
| Index of Refraction | 1.547 |
| Stability | Air and Light Sensitive |
CHEMICAL IDENTIFICATION
HEALTH HAZARD DATAACUTE TOXICITY DATA
MUTATION DATA
|
| Symbol |
GHS02, GHS06, GHS08 |
|---|---|
| Signal Word | Danger |
| Hazard Statements | H225-H301 + H311 + H331-H370 |
| Precautionary Statements | P210-P280-P302 + P352 + P312-P304 + P340 + P312-P370 + P378-P403 + P235 |
| Personal Protective Equipment | Eyeshields;Faceshields;full-face particle respirator type N100 (US);Gloves;respirator cartridge type N100 (US);type P1 (EN143) respirator filter;type P3 (EN 143) respirator cartridges |
| Hazard Codes | T+:Verytoxic; |
| Risk Phrases | R26/27/28;R63 |
| Safety Phrases | S36/37/39-S45 |
| RIDADR | UN 2811 6.1/PG 1 |
| WGK Germany | 3 |
| RTECS | FZ4645000 |
| Packaging Group | I |
| Hazard Class | 6.1(a) |
| HS Code | 2942000000 |
| Precursor 6 | |
|---|---|
| DownStream 1 | |
| HS Code | 2942000000 |
|---|